Sign inJoin waitlistJoin the waitlist

PZ

Pan Zheng

Physician · Univ of Maryland Sch of Med

Credentials: · · · · ·

History

Univ of Maryland Sch of Med
Present

Pathology-Anatomic and Clinical

Research

Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control
Genes & Development · 2007 · 2,625 citations
CD24 and Siglec-10 selectively repress tissue damage-induced immune responses
Science · 2009 · 680 citations
TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species
The Journal of Experimental Medicine · 2008 · Last of 7 authors · 584 citations

KM
Kenneth May
8 papers · 3 as a resident
YW
Yingchun Wang
8 papers
EK
Ergun Kocak
6 papers · 6 as a fellow
MC
Michael Caligiuri
6 papers
Tao Zuo
6 papers
Zihai Li
5 papers
Anthony Sandler
3 papers
Carlos Malvestutto
3 papers
PR
Pavan Reddy
3 papers
Tianhong Li
3 papers
Berge Minassian
2 papers
Chen Liu
2 papers

Grants

A Mouse Model to Assess Long Term Immunotherapy-Related Adverse Effects in Children
National Cancer Institute · R01
Contact PI · $835.9K · University of Maryland Baltimore
2018–2023
First in Human Phase I/II Clinical Trial of ONC-392: Preserving CTLA-4 Immune Tolerance Checkpoint for Safer and More Effective Cancer Immunotherapy
National Cancer Institute · R44
Contact PI · $2.4M · oncoc4, Inc.
2020–2023
Cindi Study: A Phase II Clinical Trial to Combine CD24Fc with Ipilimumab and Nivolumab to Decrease Immune Related Adverse Events (irAE)
National Cancer Institute · R44
Contact PI · $396.7K · Oncoimmune, Inc.
2020–2021
SAC-COVID: An FDA-Approved Phase III Clinical Trial Evaluating the Safety and Therapeutic Efficacy of CD24Fc in Severe COVID-19 Patients
National Cancer Institute · R44
Contact PI · $3M · Oncoimmune, Inc.
2019–2021